RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development. In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products. As Curemark continues to anticipate expansion of its clinical trials program, Szigethy will oversee and coordinate all activities across a variety of Curemark product programs, the company said.
Dr. Joan Fallon, Curemark's Founder and CEO said, "We are very excited to have James assume this new position. Curemark has a strong focus on innovation coupled with excellence and James' credentials as an experienced pharmacist and consultant are a tremendous asset to us."
"I am excited to have the opportunity to implement Curemark's strategic vision and this is a truly exciting company to work for," remarked Szigethy. "Curemark is focused on children with conditions for whom either no treatment or inadequate treatment is available and I am proud to be at the forefront of the development of new products to further our studies and Curemark's mission."
Szigethy's new responsibilities will include formulation development, overseeing Curemark's product production and expansion of its product portfolio. He has been with the company since 2007.
Szigethy graduated from St. John's University in 1994 with a B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and became a supervising pharmacist for Wal-Mart, where his department was recognized as Wal-Mart's Northeast Region Pharmacy of the Year in 2006.
Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of t